Form 6-K GLAXOSMITHKLINE PLC For: Jul 25
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 25 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') | ||
a) |
Name |
Dr K Slaoui | |
b) |
Position/status |
PCA of Dr M M Slaoui (Chairman, Global Vaccines) | |
c) |
Initial notification/
amendment |
Initial notification | |
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) |
Name |
GlaxoSmithKline plc | |
b) |
LEI |
5493000HZTVUYLO1D793 | |
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||
a) |
Description of the financial instrument |
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053 | |
b) |
Nature of the transaction |
An increase of 1 ADS following the notional allocation of ADSs on 22 July 2016, at a price of $43.88 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
| |
c) |
Price(s) and
volume(s) |
Price(s) |
Volume(s) |
$43.88 |
1 | ||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction) | |
e) |
Date of the transaction |
2016-07-22 | |
f) |
Place of the transaction
|
n/a
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 25, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMAX Corporation Reports First Quarter 2024 Earnings Results
- C2P Congratulates Dave Alison for Being Named an Excellence Awardee Finalist for the 2024 InvestmentNews Awards
- Silver Spike Investment Corp. Announces First Quarter 2024 Financial Results Conference Call
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!